|
Top 6 Reasons to
Watch
this Stock
1. HUGE MARKET - The
total cardiovascular stent market in 2005 was approximately $7
billion in 2005.
2. PRODUCT
RECOGNITION - Drug/device merchandise has
gained significant popularity and represents approximately 70%
of the market.
3. STRATEGY ON
TARGET - MIVT cites growing body of scientific
evidence validating company's strategy.
4. ADVANCED STAGES OF
RESEARCH - Successful pre-clinical trials
completed with additional trials underway.
5. MARKET GROWTH -
MIVT expands into the $1B stroke business. Positive
results obtained from advanced exploratory studies on the
company's stroke prevention device (AEPD) pave the way for
further full-scale animal and human clinical trials and
ultimately, FDA approval and commercialization.
For more information on
MIV
Therapeutics,
visit them on the
World Wide Web
at:
http://www.mivtherapeutics.com/
BTL wishes to send
information tointerested readers
only!
If you do not
wish to receive any further information from BTL, please
followthe instructions at the bottom of the page to
unsubscribe.
For
further inquiries, please do not hesitate tocontact us at:
address@hidden | | |
MIV Therapeutics Announces Company's
Biocompatible Stents Matches
Outperforms World's Leading
Drug-Eluting Stent in Key Categories
Excellent Results from Preclinical Study
of
Biocompatible Polymer Free
Drug-Eluting Stent Coating
Technologies
Paves the Way Towards Human
Trials
ATLANTA, GA - November 29, 2006
- MIV Therapeutics, Inc. (OTCBB:MIVT;FWB:MIV), a leading
developer of next-generation biocompatible polymer-free
drug-eluting stents and advanced drug delivery systems,
announced today that a comparative animal study of two of its
novel polymer-free drug-eluting stent coating technologies has
concluded with positive results.
This study compared stents
coated with MIVT's polymer-free drug-eluting technologies to
the J&J CypherTM stent, one of
the world's best selling drug-eluting stent.
The Study successfully demonstrated that both of
MIVT's proprietary, polymer-free, Sirolimus eluting coatings
are at least as good as Johnson & Johnson's
CypherTM
Stent.
The study also demonstrated
MIVT's coatings' potential and efficacy when compared to
CypherTM.
The independently conducted
four-week porcine study, performed by theDepartment of
Cardiology, Thoraxcenter, Erasmus University Medical Cen! ter
in the Netherlands, indicated that three variations of MIV's
polymer-free drug-eluting coatings were at least as effective
as - and in some cases, better than - Johnson &
Johnson's CypherTM, one of the
world's leading drug-eluting cardiovascular stents.
Dr Willem J. van der Giessen,
MD, PhD, Interventional Cardiologist and Dr. Heleen M.M van
Beusekom, PhD, Experimental Cardiology, from the Thoraxcenter
at the Erasmus University Medical Center were the study
directors.
The objectives of the study
were to evaluate the safety of MIVT's Hydroxyapatite coating
and to assess the efficacy of MIVT Sirolimus coated stents in
a porcine coronary model.
The results from the first part
of the study, conducted with no drug added to the coatings,
showed that HAp coated stents and bare metal stents did best
and performed equally well.
The results from the second
part of the study, with drugs added to the coatings, showed
that all of the MIVT drug-eluting technologies performed at
least as well, and in some cases better than the industry's
benchmark, the J&J CypherTM
stent.
The study concluded that MIV's
HAp coating, with or without drugs, demonstrated highly
promising performance. Based on these results the
company will begin preparations for human
implantation.
"The results of this study
indicate that our drug-eluting polymer-free technologies are
at least on par with the best in the world. We believe we have
very strong candidates for a superior product as we move into
the next phase of our regulatory program," said Dr. Mark
Landy, President of MIV Therapeutics.
The study was conducted in a
standard model of porcine coronary arteries and utilized
angiography and histology to evaluate tissue response to
stents coated with MIVT's proprietary polymer-free coatings in
comparison to identical bar! e metal stents and also stents
coated with MIVT's proprietary Sirolimus eluting technology to
J&J's CypherTM (Sirolimus)
stent.
MIV Therapeutics is developing
a diverse suite of Polymer-Free HAp coating formulas to
improve the biocompatibility of stents and other implantable
medical devices. Hydroxyapatite (HAp) occurs naturally in
human bones and teeth. It rapidly integrates into the human
body and has been shown to have excellent stability and
biocompatibility. HAp is non-toxic, non-thrombogenic,
noninflammatory and has been shown to promote
angiogenesis.
HAp coatings are also
expected to reduce the increased risk of deadly blood
clots currently associated with today's polymeric
drug-eluting stents. Recent information presented at leading
cardiology conferences estimated that blood clots have been
identified in at least 20,000 cases of implanted drug-eluting
stents to-date, resulting in approximately 8,000 premature
deaths.
MIVT recently announced that it intends to begin
the first human implants of a HAp Nano Film Coated stent early
in 2007.
Human implantation represents a
significant milestone in MIVT's strategic plan to develop a
new class of polymerfree drug-eluting stents that could
provide patients with superior outcomes.
About MIV Therapeutics Inc.
MIV Therapeutics is developing
a next-generation line of advanced biocompatible coatings for
passive and drug-eluting applications on cardiovascular stents
and a broad range of other implantable medical devices. The
Company's ultra-thin coating formulation is designed to
protect surrounding tissue from potentially harmful
interactions with bare metallic stents. The Company's unique
ultra-thin coating platform is derived from an organic
material called hydroxyapatite (HAp) which has demonstrated
excellent safety and biocompatibility in vivo animal studies.
Hydroxyapatite is a bioactive porous material that makes up
the bone mineral and matrix of teeth and is widely used today
as a bone substitute material and for coatings on implantable
fixation devices in orthopedic, dental and other applications.
The Company's novel polymer-free drug eluting technologies
based on Hydroxyapatite could also provide an attractive
alternative to current polymer-based drug eluting coatings on
the stent market, which have been associated with undesirable
! medical effects. The Company's drug eluting coatings are
additionally designed to suit a broad range of implantable
medical devices that could benefit from highly customizable
drug release profiles. MIVT has a Collaborative Research
Agreement (CRA) with the University of British Columbia and
has received Government grant for its research program on the
"Development of Novel Drug Eluting Composite Coatings for
Cardiovascular Stents," under the National Research
Council-Industrial Research Assistance Program (NRC-IRAP).
Under this sponsorship, the Company is expected to complete
its drug-eluting research and development program and to reach
product commercialization stage. For more information, please
visit http://www.trilogycapital.com/tcp/mivt/website.html. To
read or download MIV Therapeutics' Investor Fact Sheet, visit
http://www.trilogy-capital.com/tcp/mivt/factsheet.html
|
Forward
Looking Statements
Safe Harbor Statement
Under the Private Securities Litigation Act of 1995
--With the exception of historical information, the
matters discussed in thispress release are
forward-looking statements that involve a number of
risks anduncertainties. The actual future results could
differ significantlyfrom those statements. Factors that
could cause actual results to differmaterially include
risks and uncertainties such as the inability to finance
thecompany's operations or expansion, inability to hire
and retain qualifiedpersonnel, changes in the general
economic climate, including rising interestrate and
unanticipated events such as terrorist activities. In
some cases, youcan identify forward-looking statements
by terminology such as "may,""will," "should," "expect,"
"plan,""anticipate," "believe," "estimate,"
"predict,""potential" or "continue," the negative of
such terms, orother comparable terminology. These
statements are only predictions. Althoughwe believe that
the expectations reflected in the forward-looking
statementsare reasonable, such statements should not be
regarded as a representation bythe Company, or any other
person, that such forward-looking statements will
beachieved. We undertake no duty to update any of the
forward-looking statements,whether as a result of new
information, future events or otherwise. In light ofthe
foregoing, readers are cautioned not to place undue
reliance on suchforward-looking statements. For further
risk factors see the risk factorsassociated with our
Company, review our SEC filings.
About
Business to Leisure Monthly
(BTLmonthly.com)
Businessto Leisure Monthly is "For
Readers with Ambition" and its sisterpublication BTL
Mid-Month Report are online magazines that are each sent
outonce per month by email through numerous distribution
partners. Thesepublications reach millions of opt-in
subscribers. The online magazines focuson Corporate
Profiles from companies involved within the stock
markets alongwith Business, Lifestyle, and Leisure
articles produced by BTL and theircontributing writers.
An additional publication, BTL Breaking News Bulletin,
issent out to millions of investors numerous times each
month and is well knownfor its "Top 5 Reasons to Watch
this Stock". BTL also produces SectorReports, BTL
Canada, general advertising packages, identity branding,
and somuch more. Please feel free to contact BTL at
address@hidden.
DISCLAIMER
All material herein isinformation
supplied by the company or other sources believed to be
reliable.The information contained herein is not
guaranteed by Business to LeisureMonthly Inc. (a
subsidiary of BTL Media, Inc.) to be accurate, and
should notbe considered to be all-inclusive. The
companies that are discussed in thisprofile have
approved the statements made in this profile. This
profilecontains forward-looking statements that involve
risks and uncertainties.Statements in this press release
about the Company's future expectations otherthan
historical facts, are "forward-looking statements"
within themeaning of section 27A of the Securities Act
of 1933, section 21E of theSecurities Act of 1934, as
that term is defined in the Private SecuritiesReform Act
of 1995. It is important to note that actual results and
ultimatecorporate actions could differ materially from
those in such forward lookingstatements. Such
"forward-looking statements" are subject to risksand
uncertainties set forth from time to time in the
Company's SEC reports thatcould cause results to differ
materially from those expressed or impliedinclude, but
are not limited to, the results of future tests and
theavailability of funding for additional research and
development. This materialis for informational purposes
only and should not be construed as an offer
orsolicitation of an offer to buy or sell securities.
Business to Leisure Monthlyis not a licensed broker,
broker dealer, market marker, investment advisor,analyst
or underwriter. Please consult a broker before
purchasing or sellingany securities viewed on
www.btlmonthly.com. Business to Leisure Monthlyintends
to sell any shares owned within the next 60 days.
Business to LeisureMonthly received compensation of
forty thousand dollars to perform investor relations
services for MIV Therapeutics. Business to Leisure
Monthly affiliates, officers, directors andemployees may
also have bought or may buy the shares discussed in this
profileand may profit in the event those shares rise in
value. Business to LeisureMonthly does not and will not
offer any opinion as to when others should sell;each
investor must make that decision based on his or her
judgment of themarket.
| | |
| | ![]()
|